Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types

BACKGROUND: Multiple PD-L1 immunohistochemistry (IHC) assays, including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1 IHC assays, have been approved by the Food and Drug Administration as a companion diagnostic (CDx) for various antiprogrammed death-1 and antiprogrammed death ligand 1 (PD-L1) based...

Descripción completa

Detalles Bibliográficos
Autores principales: Maule, Jake G, Clinton, Lani K, Graf, Ryon P, Xiao, Jinpeng, Oxnard, Geoffrey R, Ross, Jeffrey S, Huang, Richard S P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621188/
https://www.ncbi.nlm.nih.gov/pubmed/36302564
http://dx.doi.org/10.1136/jitc-2022-005573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621188/
https://www.ncbi.nlm.nih.gov/pubmed/36302564
http://dx.doi.org/10.1136/jitc-2022-005573

Ejemplares similares